Experimental evidence for amorphous carbon grains in comets

Amorphous carbon grains similar to those produced in the laboratory, but with a higher hydrogen content, appear to be good candidates to simulate both the IR continuum emission and the 3.4 micron band measured for P/Halley. The comparison of the cometary features with those detected in the laboratory for carbon grains characterized by various sp(exp 2)/sp(exp 3) ratios seems to indicate that a prevalent diamond-like (sp(exp 3)) structure should be present in cometary particles. These kinds of solid particles seem also suitable to explain the daily and monthly variations of the 3.4 micron band intensity, relative to the continuum, and, at the same time,- to fulfill the abundance constraints. The same grains appear to be able to reproduce the absorption bands detected in the IR galactic source IRS 7. This result may be considered as a first experimental evidence of a relation existing between interstellar dust and cometary materials

Raman properties of various carbonaceous materials and their astrophysical implications

It is well known that a large number of celestial objects exhibit, in the range 3 to 12 micron, a family of emission features called unidentified infrared bands (UIR). They usually appear together and are associated with UV sources. Recently various authors have suggested that these features could be attributed to solid carbonaceous materials. Following this interest, a systematic analysis was performed of various types of amorphous carbon grains and polycyclic aromatic hydrocarbons (PAH), produced in lab. Updating results of Raman measurements performed on several carbonaceous materials, chosen according to their astrophysical interest, are presented. The measurements were made by means of a Jobin-Yvon monochromator HG2S and standard DC electronic. The line at 5145 A of an Ar+ laser was used as excitation source

Lipid profile improvement in virologically suppressed hiv-1-infected patients switched to dolutegravir/ abacavir/lamivudine: Data from the SCOLTA project

open13noIntroduction: Metabolic disorders are common amongst HIV-infected patients. Data from real-life setting on the impact of DTG/ABC/3TC in virologically suppressed HIV-infected patients are scarce. Methods: We investigated the modification of metabolic profile including fasting glucose, lipid profile and markers of insulin resistance (IR) in experienced patients switching from a boosted protease inhibitors (bPI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen to DTG/ABC/3TC in a prospective, observational, multicenter study. Results: We enrolled 131 HIV-infected patients, of whom 91 (69.5%) males, mean age was 50.5±10.6 years. CDC stage was A in 66 (50.4%) patients, of whom 91 (69.5%) had acquired HIV through sexual contacts. The previous regimen was bPI-based in 79 patients (60.3%) and NNRTI-based in 52 (39.7%). Patients switching from NNRTI showed a significant reduction at week 24 in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL). Triglycerides/high-density lipoprotein cholesterol (TG/HDL) ratio, HDL, median TG and TG/HDL ratio did not show significant modification during follow-up times. Among patients switching from a bPI, we observed a significant reduction in TC and LDL at both follow-up times and a slight increase in HDL. Triglycerides/HDL ratio, median TG and TG/HDL ratio showed a decrease over time that became significant at weeks 24 and 48. Blood glucose levels did not significantly vary during the observation period in patients switching from both bPI and NNRTI-based regimens. Conclusion: Our data suggest an improvement in lipid profile and TG/HDL ratio in pretreated HIV-1-infected patients who switched to DTG/ABC/3TC over 48 weeks, especially in those previously receiving a bPI-based regimen.openBagella P.; Squillace N.; Ricci E.; Gulminetti R.; De Socio G.V.; Taramasso L.; Pellicano G.; Menzaghi B.; Celesia B.M.; Dentone C.; Orofino G.; Bonfanti P.; Madeddu G.Bagella, P.; Squillace, N.; Ricci, Elena; Gulminetti, R.; De Socio, G. V.; Taramasso, L.; Pellicano, G.; Menzaghi, B.; Celesia, B. M.; Dentone, C.; Orofino, G.; Bonfanti, P.; Madeddu, G

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

Objectives: The development of novel antiviral agents active against Hepatitis Delta Virus (HDV) might change the natural history of chronic infection, reducing the risk for end-stage liver disease. People living with HIV (PWH) are at risk for bloodborne pathogens infection, but limited data on epidemiology of HDV infection is available in this setting. The aim of this study was to investigate HDV prevalence and attitude toward HDV testing and treatment in infectious diseases centers. Methods: A cross sectional survey was performed among centers participating in the CISAI (Coordinamento Italiano per lo Studio dell’Allergia in Infezione da HIV) Group. The survey addressed anti-HDV prevalence and HDV-RNA detectability rates in PWH as well as perceived obstacles to treatment. Results: Overall, responses from ten sites were collected. Among participating centers, 316 PWH with HBV chronic infection are currently followed. Of them, 15.2% had positive anti-HDV antibodies, while 13.9% were not tested yet. Overall, 17% of anti-HDV positive PWH tested at least once for HDV-RNA had active HDV infection, and 71% of them had advanced liver disease. Most infectious diseases centers intend to treat locally HDV infection with upcoming anti-HDV drugs, but some concerns exist regarding treatment schedule. Discussion: HDV testing needs to be implemented in PWH. At present, few patients followed in the CISAI centers seem to be candidate to receive new direct active anti-HDV agents, but repeated HDV-RNA measures could change this proportion

VUV-visible measurements on different samples of amorphous carbon

Among various candidate materials for interstellar dust, amorphous carbon (AC) is playing an increasingly important role (Greenstein, 1981; Hecht et al., 1984; Jura, 1983, 1986). Furthermore, recent in situ measurements have clearly shown the presence of carbonaceous grains in the coma of comet Halley (Kissel et al., 1986). Laboratory investigations on AC grains may be very useful to better interpret observations and to support theoretical elaborations. Recently, the authors started an international research program which also includes UV extinction analyses on AC samples, by using synchrotron light. Preliminary results obtained in a first shift of measurements, last June, are given. At the present stage of the data analysis, the authors can only draw some preliminary considerations. A wide band falling at around 240 nm is detected in all the analyzed samples. It intensity seems to decrease with increasing the dust collecting distance. A peak at 150 nm decreases in intensity with increasing the collecting distance. The band seems absent in the samples characterized by a larger amount of dust. A feature at about 200 nm is detected in some samples. At the moment the authors tend to attribute it to the transmission properties of the LiF substrates at the wavelength and/or to some problems in the experimental setup. It is unclear if a hump at 120 nm is real or due to instrumental effects. The profile of the spectra does not show substantial changes when the samples are cooled down to about 100 K. The present results appear to be in general agreement with previous findings, but their analysis is in progress and the interpretation is still on the way

The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years

Geriatric Patients Living with HIV/AIDS (GEPPO) is a new prospective observational multicentre cohort consisting of all the HIV-positive geriatric patients being treated at 10 clinics in Italy, and HIV-negative controls attending a single geriatric clinic. The aim of this analysis of the GEPPO cohort was to compare prevalence and risk factors of individual non-communicable diseases (NCD), multi-morbidity (MM) and polypharmacy (PP) amongst HIV positive and HIV negative controls at enrolment into the GEPPO cohort